Enable JavaScript to visit this website.


(hydroxocobalamin for injection)


You Are Now Leaving the MeridianMeds.com Website

Links to other sites are provided as a convenience to the viewer.

Pfizer accepts no responsibility for the content of linked sites.

Product image Mobile: 

If cyanide poisoning is known or suspected, time may be running out. Treat with CYANOKIT—an FDA-approved treatment option for cyanide poisoning. Learn more about the signs and symptoms of cyanide poisoning and how CYANOKIT may help at CYANOKIT.com.7

Product indication: 


CYANOKIT is indicated for the treatment of known or suspected cyanide poisoning. If clinical suspicion of cyanide poisoning is high, CYANOKIT should be administered without delay.


Product Especification: 
To order or request a quote, call 1-800-638-8093
Key Product Specifications8:
DeliversFull starting dose of 5 g of hydroxocobalamin in a single vial; diluent for infusion not included
Administration TypeIntravenous infusion
DimensionsW: 194 mm x L: 100 mm x H: 97 mm
Packaged1 kit per box
Kit ContainsOne 250-mL glass vial containing 5 g lyophilized hydroxocobalamin for injection; one sterile transfer spike; one sterile intravenous infusion set; one package insert; one quick-use reference guide
Storage: Lyophilized FormStore at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F) [See USP Controlled Room Temperature].

CYANOKIT may be exposed, during short periods, to temperature variations of usual transport, transport in the desert, and freezing/defrosting cycles.

  • Usual transport defined as 15 days subjected to temperatures ranging from 5°C-40°C (41°F-104°F)
  • Transport in the desert defined as 4 days subjected to temperatures ranging from 5°C-60°C (41°F-140°F)
  • Freezing/defrosting cycles defined as 15 days subjected to temperatures ranging from -20°F-40°C (-4°F-104°F)
Storage: Reconstituted Drug ProductOnce reconstituted, hydroxocobalamin is stable for up to 6 hours at temperatures not exceeding 40°C (104°F).
Do not freeze.
Any reconstituted product not used by 6 hours should be discarded.
Prescription RequiredYes


For medical: 

Adverse Event or Product Quality Complaints

If you wish to report an adverse event or product quality complaint, please call: 1-800-438-1985.

Medical Information

If you have a medical question concerning Meridian products, please call:
1-800-438-1985. US HCPs can visit www.pfizermedinfo.com.

Product image Desktop: 
Product trademark: 
Download a product specifications PDFView full Prescribing Information for CYANOKIT® (hydroxocobalamin for injection) 5 g ORDER OR REQUEST A QUOTE Visit CYANOKIT.com
CYANOKIT is a registered trademark of SERB Sarl, licensed by Meridian Medical Technologies, Inc., a Pfizer company.
Important Safety Information and Indication

CYANOKIT (hydroxocobalamin for injection) 5 g

Cyanide poisoning may result from inhalation, ingestion, or dermal exposure. Prior to administration of CYANOKIT, smoke-inhalation victims should be assessed for: exposure to fire or smoke in an enclosed area; presence of soot around the mouth, nose, or oropharynx, and altered mental status. In addition to CYANOKIT, treatment of cyanide poisoning must include immediate attention to airway patency, adequacy of oxygenation and hydration, cardiovascular support, and management of any seizure activity.

Use caution in the management of patients with known anaphylactic reactions to hydroxocobalamin or cyanocobalamin. Consideration should be given to use of alternative therapies, if available. Allergic reactions may include: anaphylaxis, chest tightness, edema, urticaria, pruritus, dyspnea, and rash. Allergic reactions including angioneurotic edema have also been reported in postmarketing experience.

Acute renal failure with acute tubular necrosis, renal impairment, and urine calcium oxalate crystals have been reported following CYANOKIT therapy. Monitor renal function for 7 days following CYANOKIT therapy.

Substantial increases in blood pressure may occur following CYANOKIT therapy. Elevations in blood pressure (≥180 mmHg systolic or ≥110 mmHg diastolic) were observed in approximately 18% of healthy subjects receiving hydroxocobalamin 5 g and 28% of subjects receiving 10 g.

Usage may interfere with some clinical laboratory evaluations. Also, because of its deep red color, hydroxocobalamin may cause hemodialysis machines to shut down due to an erroneous detection of a "blood leak." This should be considered before hemodialysis is initiated in patients treated with hydroxocobalamin. Due to potential photosensitivity, patients should avoid direct sun until erythema resolves.

There are no adequate and well-controlled studies of CYANOKIT in pregnant women. CYANOKIT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Safety and effectiveness of CYANOKIT have not been established in pediatric patients.

The most common adverse reactions (>5%) included transient chromaturia, erythema, oxalate crystals in urine, rash (predominantly acneiform), increased blood pressure, nausea, headache, decreased lymphocyte percentage, and injection site reactions.


CYANOKIT is indicated for the treatment of known or suspected cyanide poisoning. If clinical suspicion of cyanide poisoning is high, CYANOKIT should be administered without delay.